To investigate the impact of Shenqi Gankang tablets on clinical efficacy and immune function in the treatment of chronic hepatitis B (CHB).
A total of 182 patients with CHB from Department of Infectious Diseases, the First Affiliated Hospital of Xinxiang Medical University between January 2017 to December 2019 were collected. All patients were randomly divided into control group (n=91) and observation group (n=91). The control group was given entecavir maleate tablets, 0.5 mg/time, one time/d and the observation group was additional given Shenqi Gankang tablets, 2.1 g/time, 3 times/d on the basis of the control group. Two groups were treated for 6 months. The differences of clinical efficacy, liver function index (AST、ALT), liver fibrosis index (LN、HA、PCⅢ, Ⅳ-C), T lymphocyte subsets index (CD4+, CD8+, CD4+/CD8+), cytokine levels index (IFN-γ, IL-2, IL-4, IL-10) and incidence of adverse reactions between two groups were compared after treatment.
The total effective rates in the observation group was significantly higher than control group (P=0.014). After treatment, the ALT, AST, LN, HA, PCⅢ, Ⅳ-C, CD8+ cells, IL-4, IL-10 of two groups were significantly reduced, while CD4+ cells, CD4+/CD8+ ratio value, IFN-γ, IL-2 were significantly increased, with statistically significant differences between two groups before and after treatment (P<0.05). After treatment, the ALT, AST, LN, HA, PCⅢ, Ⅳ-C, CD8+ cells, IL-4, IL-10 of the observation group were significantly lower than that of the control group, while CD4+ cells, CD4+/CD8+ ratio value, IFN-γ, IL-2 were higher than that of the control group, with statistically significant differences (P<0.05). The incidence of adverse reactions in control and observation group was 13.19% and 12.08%, respectively. There was no significant difference between the two groups (P=0.823).
Shenqi Gankang tablet is safe and effective in the treatment of CHB, and it could significantly improve liver function and alleviate the degree of liver fibrosis. Shenqi Gankang tablet can also promote Th1 cell immune response and enhance immune function.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |